Anti-tumor effect of CDA-II on a human glioma cell
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
To examine the effect of uroacitide (CDA-II ), an extraction product from normal human urine, on proliferation and differentiation of human glioma SWO-38 cells.
The effects of CDA-II on cellular survival and colony formation were determined by MTT and colony-formation assays. The in vivo anti-tumor effect of CDA-II was examined on transplanted SWO-38 cells in nude mice. In addition, the aterations in cell morphology induced by CDA-II were observed by H&E staining.
Treatment of SWO-38 cells with 1–5 mg/ml of CDA-II for 3 days, resulted in 39.49%± 5.27%~65.05%± 5.89% growth inhibition with an IC50of 2.52 mg/ml. Based on the colony-formation assay, 10 days of CDA-II treatment at a level of 0.3~2.1 mg/ml caused 23.45%± 0.62%~96.22%±1.01% inhibition with an IC50 of 1.03 mg/ml. Furthermore, the inhibitory response was dose-dependent. CDA-II at dosage of 500 mg/kg or 2,000 mg/kg per day for 4 weeks significantly suppressed the growth of human glioma SWO-38 cells in nude mice, with inhibition being 47.77% and 79.94%, respectively (P< 0.05, n=10). H&E staining and light microscopy revealed that CDA-II induced differentiation of the SWO-38 cells.
CDA-II has a significant anti-tumor effect on the human glioma SWO-38 cells, and is a potential and natural anti-glioma therapeutic reagent.
- Mizunno M, Yoshida J. Tumor necrosis factor-α gene transfer augments anti-fas antibody-mediated apoptosis in human glioma cell. Jpn Cancer Res. 1996, 87:543–547.
- Liao MC. A clever anticancer drug CDA-H. Taipei: ShiMao publisher. 1999; 149–161.
- Zhong XY, Chen YX, Ye SF, et al. Establishment of two cell sublines from SWO-38 glioma cells: an immunohisto-chemical and ultrastructural Study. Int J Modern Cancer Therapy. 2000; 3:34–37.
- Marcantonio D, Panasci LC, Hollingshead MG, et al. 2-Chloroethyl-3-sarcosinam ide-1-nitrosourea, a novel chloroethyl nitrosourea analogue with enhanced antitumor activity against human glioma xenografs. Cancer Res. 1997; 57:3895–3898.
- Skapek SX, Vandellen AF, McMahon DP, et al. Melphalaninduced toxicity in nude mice following pretreatment with buthionine sulfoximine. Cancer Chem Pharmacol. 1991; 28: 15–21. CrossRef
- Sato etol. Eradicate cancer. Taipei: ShiMao publisher. 1997; 226–231.
- Burynski SR. Antineoplastons: History of the research (1). Drugs Exp Clin Res. 1986; 12:1–9.
- Feng PY, Li Q, Wang ZJ, et al. The clinic study of CDA-H improve life quality of terminal malignancy patient. China Cancer. 2002; 11:108–200.
- Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R&D. 2003; 4:91–101. CrossRef
- Liu JW, Tang Y, Shen Y, et al. Antitumor effect of arsenic trioxide in combination with uroacitides on hepatocellular carcinoma. Chin J Gen Surg. 2003; 18:114–116.
- Liu JW, Tang Y, Shen Y, et al. Apoptosis threshold of hepatoma cell lines induced by As2O3 and CDA-II. Chin J Exp Surg. 2003; 20:116–117.
- Liu JW, Tang Y, Shen Y, et al. Synergistic effect of cell differentiation agent II and arsenic trioxide on induction of cell cycle and apoptosis in hepatotumor cells. World J Gastroentero. 2003; 9:65–68.
- Lin WC, Wu YW, Lai TY, et al. Effect of CDA-II, urinary preparation, on lipofuscin, lipid peroxidation and antioxidant systems in young and middle-aged rat brain. Am J Chin Med. 2001; 29:91–99. CrossRef
- Natarajan V, Scribner WM, Al-Hassani M, et al. Reactive oxygen species signaling through regulation of protein tyrosine phos-phorylation in endothelial cells. Environ Health Perspect. 1998; 106:1205–1212. CrossRef
- Anti-tumor effect of CDA-II on a human glioma cell
Chinese Journal of Clinical Oncology
Volume 2, Issue 3 , pp 679-684
- Cover Date
- Print ISSN
- Online ISSN
- Chinese Anti-Cancer Association
- Additional Links
- anti-tumor effect
- induced differentiation